Company Overview
Cybin Inc. operates as a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics specifically for patients suffering from mental health conditions. The firm is currently advancing CYB003, a deuterated psilocybin analog, which is progressing through a phase 3 clinical trial to treat major depressive disorder, alongside CYB004, a deuterated analog with ongoing development. This enterprise functions within the Healthcare sector, specifically categorized under the Biotechnology industry, a space defined by high research and development expenditures and reliance on successful clinical outcomes for commercial viability. The company holds a market capitalization of $413.12M and employs a workforce of 50 individuals, indicating a small-cap structure typical of early-stage biopharmaceutical entities. The limited market cap and absence of reported annual revenue figures suggest that the company's current valuation is driven primarily by its intellectual property pipeline and potential future commercialization prospects rather than established cash-flow-generating operations.
Financial Health
The company reports no reported revenue for the trailing twelve months, with a net income of $-86,798,672 and an EBITDA of $-98,725,328, illustrating a significant operational deficit where costs substantially exceed any top-line activity. The reported gross margin of 0.0% and operating margin of 0.0% reflect the current stage of development where costs are incurred without corresponding sales to generate profit, while the profit margin of 0.0% confirms the absence of net profitability. Free cash flow stands at $-65,267,852, which indicates that the company is burning cash to fund its research and development efforts rather than generating liquidity from operations. Despite the negative cash flow, the balance sheet maintains $83.75M in cash against $28.89M in debt, providing a liquidity buffer to support ongoing clinical trials. The debt-to-equity ratio is 20.78, and the current ratio is 8.57, suggesting that while the company carries leverage relative to equity, it possesses a robust short-term liquidity position capable of covering current obligations multiple times over. Return on Equity is -53.0% and Return on Assets is -32.9%, metrics that reveal management is utilizing shareholder and asset bases to fund growth initiatives rather than generating immediate financial returns.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is -2.82, a figure that implies the market is pricing in future earnings potential that does not yet exist in the current period's financial statements. The price-to-book ratio is 1.55, indicating that the market values the company at a premium of 55% over its net asset value, likely reflecting the perceived value of its clinical-stage assets. The price-to-sales ratio is N/A and the EV/EBITDA is -3.35, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable given the company's current financial structure and negative earnings profile. The stock has traded between a 52-week high of $10.72 and a 52-week low of $4.81, with the current price trading below the high and above the low, reflecting ongoing volatility within the biotechnology sector. The beta value is 0.79, which indicates that the stock exhibits lower volatility relative to the broader market, moving with less intensity than the general equity index despite the inherent risks associated with clinical-stage development.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet achieved positive revenue or earnings to calculate these growth rates. Because the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings and cash flow are theoretically available for reinvestment into growth initiatives rather than distribution to shareholders. The absence of a dividend payout ratio confirms that the company is not obligated to pay dividends and is instead retaining capital to sustain its clinical trial programs and operational expenses. Consequently, the overall growth and income profile is characterized by an exclusive focus on capitalizing the pipeline through reinvestment, with no current income generation from dividends or sales.